Goldman Sachs Group (GS)

Goldman Sachs analyst maintains Neutral rating on Tesla with price target of $235, citing importance of leveraging FSD in China's large vehicle market.

Ford's first-quarter 2025 earnings exceeded forecasts, with an adjusted EPS of $0.14, outperforming estimates. Despite tariff challenges, Ford maintains a strong position in the U.S. truck market. Analysts note a solid outlook, though the company has suspended its 2025 guidance amid supply chain and policy uncertainties. Goldman Sachs raised the price target, while BofA reiterated a Buy rating.

Expectations are low for the media bellwether heading into an important financial update on Wednesday.

There are plenty of good ones to choose from, but these three are all undervalued, leaving them ripe for a lot of bullishness sooner than later.

Shares of healthcare services company Sotera Health (NASDAQ:) jumped 5.9% in the pre-market session after Goldman Sachs analyst Matthew Sykes upgraded the stock from Neutral to Buy and raised the price target from $14 to $17. Sykes emphasized that SHC's consistent exposure to the commercial pharmaceutical and medical device sectors, both of which are considered essential and relatively insulated from economic cycles, positions the company as a more compelling investment amid growing macroeconomic uncertainty.

Goldman Sachs upgrades Sotera Health to Buy, citing tariff immunity, legal clarity, and exposure to Medtech innovation for future growth.

OPEC+ hike in production and Goldman's oil price forecast decrease led to a selloff in US energy stocks. Brent and WTI may drop to $40s by 2026.

Amazon beat Q1 expectations and analysts are very much bullish, with some price targets calling for almost 50% upside from current levels.

Apprehensions regarding deal closure, Trump’s tariff threat, earnings anxiety and a delayed product launch led to a spike in activity levels for these stocks.

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.

Some believe that the rise in gold is far from over. With $4,000 evoked, see these three investments with big variations in possible risk and return outcomes.

Goldman Sachs said the expected drop in Q2 attendance may have to do with the Easter shift to April, potentially pushing travel plans from March.

Goldman Sachs analyst expects GM's FY25 guidance cut due to tariff uncertainty. Current policy could cost GM $4-5 billion, leading to revised EPS.

Goldman Sachs lowers its price target to $85 from $103, with several other analysts making similar downward revisions.

President Donald Trump deflects blame for the U.S. economy's 0.3% contraction in the first quarter onto his predecessor, despite clear evidence indicating otherwise.

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations and national security concerns.

Starbucks (NASDAQ: SBUX) missed Q2 FY25 expectations, prompting Goldman Sachs to downgrade the stock to Neutral with a lower price target of $85. Analysts cite soft North America sales, declining consumer sentiment, and ongoing macroeconomic pressures as key concerns.

Goldman Sachs analyst maintained Buy rating and $388 PT for Caterpillar Inc. despite Q1 revenue decline and EPS miss due to expected tariff costs.

Amazon has rebounded 16% into earnings as analysts remain overwhelmingly bullish, with targets up to $250 and strong AWS and AI growth expected.

Here are three retail stocks with heavy exposure to China and other Asian countries that are facing higher tariffs from the United States